Marking World Psoriasis Day on Oct 29, a public welfare initiative was launched in Beijing to raise awareness of fair development opportunities for people living with psoriasis. The program seeks to promote a more inclusive society and help patients overcome disease-related limitations through standardized treatment and improved access to care.

The initiative was led by Johnson & Johnson Innovative Medicine with philanthropic support from the Minsheng Weekly magazine under People's Daily.

"A return to normal life for psoriasis patients hinges on long-term, stable disease control," Li Ruoyu, director of Dermatology at Peking University First Hospital, said. "Although psoriasis cannot be cured, international evidence indicates that with an early start on suitable biologics — beginning with a standard one-year course of treatment and continued long-term management — psoriasis patients can experience improvement in skin lesions for up to 2.5 years."

Sophia Pan, head of Immunology Division at Johnson & Johnson Innovative Medicine, said that from introducing innovative treatments to providing digital whole-cycle support, Johnson & Johnson aims to address patients' comprehensive needs beyond therapy.

A survey — the Psoriasis Patient Career Development Insight Survey — was launched at the event, aiming to identify the primary challenges and needs in patients' professional journeys. The resulting data will be used to advocate for tailored support systems and a more equitable society, enabling psoriasis patients to reach their full potential in their careers.